NCT00671515

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Joseph Calabrese, MD · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).

Conditions

• Depressive Disorder, Major
• Metabolic Syndrome X

Interventions

Type	Name	Description
DRUG	Pioglitazone	An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.

Timeline

• Start date: 2008-04-01
• Primary completion: 2011-08-01
• Completion: 2011-11-01
• First posted: 2008-05-05
• Last updated: 2017-01-26
• Results posted: 2014-10-17

Locations

1 site across 1 country: United States